

August 25, 2008

United States of America

Healthcare

Specialty Pharmaceuticals

Teva Pharmaceutical (TEVA - US\$ 46.79) 1-Overweight

Company Update

Richard B. Silver

1.212.526.5387

rsilver1@lehman.com

LBI, New York

Preview of ADAGIO at EFNS & ANA

Investment Conclusion

- In our view, given the recent strength in Teva shares, partly in anticipation of the EFNS presentation, we would not expect significant follow-through stock performance with the presentation, but rather steady gains going forward. Teva remains our top pick in the generic space, particularly for investors with a longer-term time horizon.

EPS (US\$) (FY Dec)

	2007		2008		2009		% Change	
	Actual	Old	New	St. Est.	Old	New	2008	2009
1Q	0.42A	0.64A	0.64A	0.64A	0.64E	0.64E	52%	0%
2Q	0.63A	0.65A	0.65A	0.65A	0.71E	0.71E	3%	9%
3Q	0.64A	0.71E	0.71E	0.70E	0.78E	0.78E	11%	10%
4Q	0.69A	0.73E	0.73E	0.75E	0.88E	0.88E	6%	21%
Year	2.38A	2.73E	2.73E	2.74E	3.00E	3.00E	15%	10%
P/E			17.1			15.6		

Summary

- Tomorrow, 8/26, at 5:40AM ET(11:40am Madrid time) at EFNS, in a 10 minute presentation, Teva will provide details on the ADAGIO study of its currently marketed Parkinson's drug Azilect. The study was designed to demonstrate slowing of disease progression, results that have not been seen with other currently marketed drugs. The details follow Teva's 6/17/08 press release which confirmed the positive results.
- While we do not assume Azilect will gain an explicit additional claim for slowing disease progression, we see the potential for greater usage just based on publication of the results in a peer-reviewed publication. Even the latter scenario provides room for upside to our current \$300M global peak sales forecast, in our view.


Market Data

Market Cap (Mil.)	N/A
Dividend Yield	1.03
52 Week Range	50.00 - 40.37

Financial Summary

Revenue TTM (Mil.)	9408.0
--------------------	--------

Stock Overview



Stock Rating

New: 1-Overweight
Old: 1-Overweight

Target Price

New: US\$ 56.00
Old: US\$ 56.00

Sector View: 2-Neutral

SUMMARY: Tomorrow, August 26 at 5:40AM ET(11:40am Madrid time) at the Annual Meeting of EFNS (European Federation of Neurological Societies), in a 10 minute presentation Teva will provide details on the successful completion of a Phase 3 randomized, multi-center, double-blind, placebo-controlled, parallel-group study, ADAGIO, which involves Teva's currently marketed Parkinson's drug Azilect (rasagiline) 1mg and was designed to demonstrate the drug can slow the progression of Parkinson's disease. **Following the presentation, Teva will issue a scientific release that will include the results of the study as they relate to the three primary endpoints, and host a press conference at 7:00-8:00am ET (1:00-2:00pm Madrid time).** In addition, Teva will make the American Neurological Association (ANA) abstract available tomorrow for the ADAGIO results to be presented at that meeting on Sept. 23 in Salt Lake City, with a link included in the press release. All the details of the EFNS presentation will be included in the ANA abstract.

Lehman Brothers does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report.

Customers of Lehman Brothers in the United States can receive independent, third-party research on the company or companies covered in this report, at no cost to them, where such research is available. Customers can access this independent research at www.lehmanlive.com or can call 1-800-2LEHMAN to request a copy of this research.

Investors should consider this report as only a single factor in making their investment decision.

PLEASE SEE ANALYST(S) CERTIFICATION(S) ON PAGE 2 AND IMPORTANT DISCLOSURES BEGINNING ON PAGE 3

Should the detailed ADAGIO data strongly confirm the topline results already released, we believe that the product's market penetration could substantially improve, as it would be the first Parkinson's Disease treatment to demonstrate an effect on disease progression rather than just treatment of symptoms. **While Teva is expected to file an sNDA prior to year-end, with an improved label likely in 2009, we believe that Azilect's market penetration could accelerate prior the label improvement, driven by the use of an expected peer-reviewed publication of the positive ADAGIO data. As a result, in addition to the quality of the ADAGIO data, we look to acceptance of the data for publication before year end as an important event, along with the actual publication to follow.** Our global Azilect sales estimates remain \$176M in 2008 and \$260M for 2009, with peak sales of \$300M, the latter still conservatively assuming no major change in usage from ADAGIO.

STOCK COMMENT: The EFNS presentation, and to some degree, related newflow at ANA, remain important near-term stock catalysts for Teva, in our opinion, given the potential for ADAGIO results to increase Azilect usage and peak sales from our current \$300M forecast. On an NPV basis, our \$300M forecast translates to \$0.68/share. In our view, given the recent strength in Teva shares, partly in anticipation of the EFNS presentation, we would not expect significant follow-through performance with the presentation, but rather steady gains going forward. More generally, with Teva being a top operator in the generic industry and well-positioned for sustainable long-term growth, we believe that the global macroeconomic environment should continue to provide buying support for the stock, particularly for long-term oriented investors. Our \$56 price target represents 18x our 2009 EPS estimate of \$3.00.

REVIEW OF PHASE 3 TOPLINE RESULTS: Recall, on 6/17/08, Teva announced successful Phase 3 completion of ADAGIO, which involves Teva's currently marketed Parkinson's drug Azilect (rasagiline) 1mg and was designed to demonstrate the drug can slow the progression of Parkinson's disease. The 1mg version met all three primary, secondary and additional endpoints, all with statistical significance, as well as confirmed the safety and tolerability of Azilect. Teva plans to submit the results to the regulatory authorities in U.S. and Europe. Based on the results, Azilect could become the first Parkinson's disease treatment to receive a label for disease modification.

ADDITIONAL DETAILS OF STUDY DESIGN: The study included three primary endpoints: 1) superiority of slopes in the placebo-controlled phase (week 12 – 36); 2) Superiority of early-start vs. delayed at week 72 (end of study); and 3) Non-inferiority of early-start vs. delayed start slopes during weeks 48-72 of the active phase. The study also included one secondary endpoint - Change in Total UPDRS scores during the PC (placebo-controlled) phase. The 4 additional endpoints were – 1) fatigue scale, 2) time to need for additional medication, 3) need of additional medication and 4) non-motor part of the PD scale (UPDRS).

The 18-month study involved 1,176 patients with early, untreated Parkinson's disease and was conducted in 14 countries and 29 medical centers. The primary analyses of the trial were based on change in total UPDRS (Unified Parkinson's Disease Rating Scale - most commonly used scale to assesses disease status) and included slope superiority of rasagiline over placebo in the placebo-controlled phase, change from baseline to week 72, and non-inferiority of early-start vs delayed-start slopes during weeks 48-72 of the active phase. ADAGIO is a randomized, multi-center, double-blind, placebo-controlled, parallel-group study prospectively examining rasagiline's potential disease modifying effects. Patients were randomized to early-start treatment (72 weeks rasagiline 1 or 2mg once daily) or delayed-start treatment (36 weeks placebo followed by 36 weeks rasagiline 1 or 2mg once daily). In addition to the 1mg results above, the 2mg dose met two of the three primary endpoints, the secondary endpoint, and was found to be safe and well-tolerated.

Analyst Certification:

I, Richard B. Silver, hereby certify (1) that the views expressed in this research Company Note accurately reflect my personal views about any or all of the subject securities or issuers referred to in this Company Note and (2) no part of my compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this Company Note.

Other Team Members:

Trimble, Ann (LBI, New York)

1.212.526.9731

atrimble@lehman.com

Company Description:

Israel-based Teva develops, manufactures & markets generic & brand pharmaceuticals, & active pharmaceutical ingredients. Largest US generic co. Over 80% of sales are from North American and Europe.

Important Disclosures:


Teva Pharmaceutical (TEVA)

US\$ 46.79 (22-Aug-2008)

1-Overweight / 2-Neutral

Rating and Price Target Chart:

TEVA PHARMACEUTICAL INDUSTRIES LTD. (ADS)



Source: FactSet

Currency=US\$

Date	Closing Price	Rating	Price Target
13-Feb-08	47.64		56.00
02-Aug-07	43.38		54.00
03-May-07	39.23		48.00
14-Feb-07	37.96		44.00
08-Nov-06	32.77		43.00

Date	Closing Price	Rating	Price Target
01-Mar-06	43.43		47.00
17-Nov-05	41.66		48.00
17-Nov-05	41.66	1 -Overweight	
15-Nov-05	39.77		0.00

FOR EXPLANATIONS OF RATINGS REFER TO THE STOCK RATING KEYS LOCATED ON THE PAGE FOLLOWING THE LAST PRICE CHART.

Lehman Brothers Inc. and/or an affiliate makes a market in the securities of Teva Pharmaceutical.

Lehman Brothers Inc. and/or an affiliate has received compensation for investment banking services from Teva Pharmaceutical in the past 12 months.

Lehman Brothers Inc. and/or an affiliate expects to receive or intends to seek compensation for investment banking services from Teva Pharmaceutical within the next 3 months.

Lehman Brothers Inc and/or an affiliate trade regularly in the shares of Teva Pharmaceutical.

Lehman Brothers Inc. has received non-investment banking related compensation from Teva Pharmaceutical within the last 12 months.

Teva Pharmaceutical is or during the past 12 months has been an investment banking client of Lehman Brothers Inc. and/or an affiliate.

Teva Pharmaceutical is or during the last 12 months has been a non-investment banking client (securities related services) of Lehman Brothers Inc.

Valuation Methodology: Our unchanged \$56 price target represents 18x our 2009 EPS estimate of \$3.00.

Risks Which May Impede the Achievement of the Price Target: A revisit of our investment rating and price target could be prompted by unexpected delays in FDA approvals of Teva's generic drug applications and/or unexpected price erosion on key products, or by a greater-than-expected slowdown in sales growth of MS drug Copaxone.

Other Material Conflicts: Lehman Brothers is acting as financial advisor to Teva Pharmaceutical Industries in the potential acquisition of Barr Pharmaceuticals. The rating, price target and estimates on Teva do not incorporate this deal.

Important Disclosures Continued:

The analysts responsible for preparing this report have received compensation based upon various factors including the firm's total revenues, a portion of which is generated by investment banking activities

Company Name	Ticker	Price	Price Date	Stock / Sector Rating
Teva Pharmaceutical	TEVA	US\$ 46.79	22-Aug-2008	1-Overweight / 2-Neutral

Guide to Lehman Brothers Equity Research Rating System:

Our coverage analysts use a relative rating system in which they rate stocks as 1-Overweight, 2-Equal weight or 3-Underweight (see definitions below) relative to other companies covered by the analyst or a team of analysts that are deemed to be in the same industry sector (the "sector coverage universe"). Below is the list of companies that constitute the sector coverage universe:

Barr Pharmaceuticals (BRL)	Elan PLC (ELN)
Endo Pharmaceuticals Holdings (ENDP)	Eurand NV (EURX)
Forest Labs (FRX)	Impax Laboratories (IPXL)
Jazz Pharmaceuticals Inc. (JAZZ)	Medicis Pharmaceutical Corp. (MRX)
MiddleBrook Pharmaceuticals, Inc. (MBRK)	Mylan Inc. (MYL)
Nektar Therapeutics (NKTR)	Par Pharmaceutical Cos. (PRX)
Sepracor Inc. (SEPR)	Teva Pharmaceutical (TEVA)
Watson Pharmaceuticals (WPI)	

In addition to the stock rating, we provide sector views which rate the outlook for the sector coverage universe as 1-Positive, 2-Neutral or 3-Negative (see definitions below). A rating system using terms such as buy, hold and sell is not the equivalent of our rating system. Investors should carefully read the entire research report including the definitions of all ratings and not infer its contents from ratings alone.

Stock Rating

1-Overweight - The stock is expected to outperform the unweighted expected total return of the sector coverage universe over a 12-month investment horizon.

2-Equal weight - The stock is expected to perform in line with the unweighted expected total return of the sector coverage universe over a 12- month investment horizon.

3-Underweight - The stock is expected to underperform the unweighted expected total return of the sector coverage universe over a 12-month investment horizon.

RS-Rating Suspended - The rating and target price have been suspended temporarily to comply with applicable regulations and/or firm policies in certain circumstances including when Lehman Brothers is acting in an advisory capacity in a merger or strategic transaction involving the company.

Sector View

1-Positive - sector coverage universe fundamentals/valuations are improving.

2-Neutral - sector coverage universe fundamentals/valuations are steady, neither improving nor deteriorating.

3-Negative - sector coverage universe fundamentals/valuations are deteriorating.

Distribution of Ratings:

Lehman Brothers Equity Research has 2076 companies under coverage.

45% have been assigned a 1-Overweight rating which, for purposes of mandatory regulatory disclosures, is classified as Buy rating, 31% of companies with this rating are investment banking clients of the Firm.

39% have been assigned a 2-Equal weight rating which, for purposes of mandatory regulatory disclosures, is classified as Hold rating, 29% of companies with this rating are investment banking clients of the Firm.

13% have been assigned a 3-Underweight rating which, for purposes of mandatory regulatory disclosures, is classified as Sell rating, 20% of companies with this rating are investment banking clients of the Firm.

Lehman Brothers Inc. and Its Foreign Affiliates Involved in the Production of Equity Research

<p>New York Lehman Brothers Inc. (LBI, New York) 745 Seventh Avenue New York , NY 10019 Member, FINRA</p>	<p>London Lehman Brothers International (Europe) (LBIE, London) 25 Bank Street London, E14 5LE, United Kingdom Regulated by FSA</p>	<p>Tokyo Lehman Brothers Japan Inc. (LBJ, Tokyo) Roppongi Hills Mori Tower, 31st Floor 6-10-1 Roppongi, Minato-ku, Tokyo 106-6131, Japan Regulated by FSA</p>
--	--	--

Mumbai Lehman Brothers Inc., India Branch (LBI, India) Winchester, Off High Street, 9th Floor Hiranandani Business Park, Powai, Mumbai 400 076, India	Seoul Lehman Brothers International (Europe) Seoul Branch (LBIE, Seoul) Hanwha Building, 12th Floor 110, Sokong-dong Chung-Ku Seoul 100-755, Korea Regulated by FSC	Hong Kong Lehman Brothers Asia Limited - Hong Kong (LBAL, Hong Kong) Two International Finance Centre 8 Finance Street, 26th Floor Central, Hong Kong Regulated by SFC
Mumbai Lehman Brothers Securities Private Limited (LBSPL, India) Ceejay House, 11th Level, Plot F, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai 400018 Regulated by SEBI	Taipei Lehman Brothers Securities Taiwan Limited (LBSTL, Taiwan) Cathay Financial Center 12F 7 Sungren Road - Shin-Yi District Taipei, Taiwan Regulated by FSC	Sydney Lehman Brothers Australia Limited (LBAUL, Sydney) Level 33, 264 George Street Sydney NSW 2000, Australia Regulated by ASIC

This material has been prepared and/or issued by Lehman Brothers Inc., member SIPC, and/or one of its affiliates (“Lehman Brothers”) and has been approved by Lehman Brothers International (Europe), authorized and regulated by the Financial Services Authority, in connection with its distribution in the European Economic Area. This material is distributed in Japan by Lehman Brothers Japan Inc., and in Hong Kong by Lehman Brothers Asia Limited. This material is distributed in Australia by Lehman Brothers Australia Limited, and in Singapore by Lehman Brothers Singapore Pte Ltd. Where this material is distributed by Lehman Brothers Singapore Pte Ltd, please note that it is intended for general circulation only and the recommendations contained herein does not take into account the specific investment objectives, financial situation or particular needs of any particular person. An investor should consult his Lehman Brothers’ representative regarding the suitability of the product and take into account his specific investment objectives, financial situation or particular needs before he makes a commitment to purchase the investment product. This material is distributed in Korea by Lehman Brothers International (Europe) Seoul Branch, and in Taiwan by Lehman Brothers Securities Taiwan Limited. Where this material is distributed by Lehman Brothers Securities Taiwan Limited, please note that recommendations expressed herein are for reference only. Investors should carefully evaluate the investment risks and are reminded that they are solely responsible for their investment decisions. This document is for information purposes only and it should not be regarded as an offer to sell or as a solicitation of an offer to buy the securities or other instruments mentioned in it. No part of this document may be reproduced in any manner without the written permission of Lehman Brothers. With the exception of disclosures relating to Lehman Brothers, this research report is based on current public information that Lehman Brothers considers reliable, but we make no representation that it is accurate or complete, and it should not be relied on as such. In the case of any disclosure to the effect that Lehman Brothers Inc. or its affiliates beneficially own 1% or more of any class of common equity securities of the subject company, the computation of beneficial ownership of securities is based upon the methodology used to compute ownership under Section 13(d) of the United States’ Securities Exchange Act of 1934. In the case of any disclosure to the effect that Lehman Brothers Inc. and/or its affiliates hold a short position of at least 1% of the outstanding share capital of a particular company, such disclosure relates solely to the ordinary share capital of the company. Accordingly, while such calculation represents Lehman Brothers’ holdings net of any long position in the ordinary share capital of the company, such calculation excludes any rights or obligations that Lehman Brothers may otherwise have, or which may accrue in the future, with respect to such ordinary share capital. Similarly such calculation does not include any shares held or owned by Lehman Brothers where such shares are held under a wider agreement or arrangement (be it with a client or a counterparty) concerning the shares of such company (e.g. prime broking and/or stock lending activity). Any such disclosure represents the position of Lehman Brothers as of the last business day of the calendar month preceding the date of this report. This material is provided with the understanding that Lehman Brothers is not acting in a fiduciary capacity. Opinions expressed herein reflect the opinion of Lehman Brothers and are subject to change without notice. The products mentioned in this document may not be eligible for sale in some states or countries, and they may not be suitable for all types of investors. If an investor has any doubts about product suitability, he should consult his Lehman Brothers representative. The value of and the income produced by products may fluctuate, so that an investor may get back less than he invested. Value and income may be adversely affected by exchange rates, interest rates, or other factors. Past performance is not necessarily indicative of future results. If a product is income producing, part of the capital invested may be used to pay that income. © 2008 Lehman Brothers. All rights reserved. Additional information is available on request. Please contact a Lehman Brothers entity in your home jurisdiction.

Lehman Brothers policy for managing conflicts of interest in connection with investment research is available at www.lehman.com/researchconflictspolicy. Complete disclosure information regarding companies covered by Lehman Brothers Equity Research, including ratings, earnings per share forecasts and price targets contained in reports covering U.S. companies is available at www.lehman.com/disclosures.